CLINICAL PAIN NEUROSCIENTIST TALKS ABOUT HOW THE BRAIN PROCESSES PAIN INFORMATION Trial: affects on pain and activity levels, by educating knee osteoarthritis participants in individualised exercise programs
With
Tasha Stanton,
Associate Professor of Clinical Pain Neuroscience
Group, Leader Persistent Pain Research Group (Lifelong Health)
SAHMRI (South Australian Health and Medical Research Institute) &
co-Director of IMPACT in Health, University of South Australia
SEGMENT
Filmed in Adelaide | March 2026
The Persistent Pain Research Group’s vision is to work hand-in-hand with consumers to undertake impactful research that helps better understand and treat persistent pain.
Their studies span discovery to implementation science to determine key contributors to the development and maintenance of persistent pain and to use this information to create novel brain-based interventions.
They hold expertise in developing new technologies, such as virtual and mediated reality, and translating these technologies to the clinical environment, using innovative co-design methods.
The Persistent Pain Research Group studies a variety of painful conditions, with specific focus on:
- Osteoarthritis
- Spinal pain (neck and back)
- Complex regional pain syndrome
- Phantom limb pain after amputation
Persistent pain affects one in five Australians and costs the nation an estimated $73 billion per year in health system costs, lost productivity and other financial costs.
Persistent pain also has debilitating personal costs – negatively impacting quality of life and the ability to engage in meaningful work and life activities.
Despite the enormity of this problem, very few effective treatments exist with most showing only small to moderate improvements. New treatments are desperately needed. The group believes the best way to create impactful change is to work with people with lived experience of persistent pain to devise solutions with them, not for them.
Source: SAHMRI webpage Persistent Pain Research Group
-
Redefining diversity in clinical trials
Ensuring inclusion, diversity, equity and patient input in the development of novel drugs and medical devices has become well accepted in health care. However appropriate implementation of these elements has been a challenge for many. Only by implementing these conscious inputs can patient outcomes be improved and health disparities in marginalised groups be addressed.
Australian Health Journal spoke to Gillian Mason, Consumer and Community Involvement Lead at Hunter Medical Research Institute in Newcastle, NSW on this topic discussed at the recent ARCS Conference in Sydney.
-
Practising to top scope of urology practice, advancing treatment & patient care through research
Michael is a urology nurse practitioner with a special interest in prostate cancer survivorship, and has worked in urology for the past ten years. Michael has completed the Prostate Nursing Care course at Latrobe University, Graduate Certificate of Health with a specialisation in Scheduled Medicines (USQ), and the Master of Nursing (Flinders) to become a Nurse Practitioner in 2024.
As a Urology Nurse Practitioner he divides his time between the Australian Prostate Centre and Western Urology.
-
1 million Australians with undiagnosed thyroid disorders remain at risk of irreparable damage
The Australian Thyroid Foundation is a national not-for-profit organisation with charity status aimed at patients and the healthcare community. The ATF’s focus is to support and educate its member base and promote our Good Thyroid Health Messaging throughout the Australian Community.
Australian Thyroid Foundation, CEO Beverley Garside attending the breakfast gave her response to the Federal Budget and the Foundation’s pre-budget submission, which was not granted.
